Just In
- 2 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 4 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 5 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
- 7 hrs ago Vidya Balan's 'Do Aur Do Pyaar' Urban Boho Style Avatar Is Relatable And Inspiring, Check Her Modern Avatar!
Don't Miss
- Education UP Board Class 10 Result Out, Prachi Nigam Tops the Exam, Check the Class 10 Topper's List Here
- News Collective Newsroom Launches As An Independent News Company
- Sports IPL 2024: CSK coach Stephen Fleming talks about space 'owned' by MS Dhoni, calls 42-year-old heartbeat of team
- Finance Elon Musk Postpones India Trip, Tesla's Indian Market Entry Delayed
- Movies Love, Sex Aur Dhokha 2: The REAL Reason Of Rajkummar Rao And Nushrratt Bharuccha Not Being Part Of The Film
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Automobiles Tesla CEO Elon Musk's Much-Awaited Visit to India Deferred, Leaving Questions Unanswered
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
India's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
Bharat Biotech on February 19 said that its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US. In a statement, Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, noted that the American health regulator -- the US Food and Drug Administration (FDA) -- has lifted its clinical hold to evaluate the COVID-19 vaccine candidate BBV152, known as Covaxin outside the US.
Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US.
Ocugen Inc is co-developing the Covaxin vaccine candidate for COVID-19 in the US and Canada.
"We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine," Ocugen CEO and co-founder Shankar Musunuri said in a statement.
He further said: "We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate."
With more than 200 million doses having been administered to adults outside the US, Covaxin is currently authorised under emergency use in 20 countries.
Applications for emergency use authorisation are pending in more than 60 other countries.
The World Health Organisation (WHO) recently added Covaxin to its list of vaccines authorised for emergency use. As many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using Covaxin.
In a separate statement on Twitter, Bharat Biotech noted that Covaxin is the only vaccine in India to have published clinical data for children 2-18 years of age while trashing a few media reports which questioned the efficacy of the jab.
These trials were conducted based on regulatory approvals by the CDSCO and DCGI, it said.
The vaccine was evaluated in 175 subjects in the 12-18 years age group, and 350 subjects in children below 12 years of age, it added.
"It was one of the few vaccines to be evaluated in children with published data. Overall, Covaxin has more than 15 publications elucidating all aspects of the safety, immunogenicity, efficacy and effectiveness, in adults and children. This level of data transparency demonstrates a high degree of confidence in the product," the company stated.
Every batch of Covaxin requires more than 250 quality control tests before it can be released for supplies, it added. The vaccine has been administered to more than 300 million subjects globally, Bharat Biotech stated.
"Since the start of the children's vaccination program on January 3, 2022, 70 per cent of the children in the 15-18 years age group have received the first dose, and more than 25 per cent of the children in the 15-18 years age group have also received their second doses," it said.
Over 7 crore doses have been administered to children since January 2022, it added.
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthGovt's Decision On COVID-19 Vaccination For Children 'Unscientific': Senior AIIMS Epidemiologist
- healthCovaxin's Shelf Life Extended To 12 Months From Date Of Manufacture
- healthExperts Allay Covaxin Concerns, Say 50% Effectiveness Against Delta-Driven COVID-19 Surge Not Bad
- healthGovernment Nod To Commercial Export Of Covishield, Covaxin In View Of Sufficient Stock
- healthCovaxin Shows 50% Effectiveness Against Symptomatic Covid-19 In Real-World Assessment: Lancet Study